Rectal nitric oxide as biomarker in the treatment of inflammatory bowel disease: Responders versus nonresponders

doi:10.3748/wjg.v12.i21.3386

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 12, Issue 21

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (3918)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-5) series, Tables (1-3) series.

Item

Count

PDF

429

HTML

2976

Figures (1-5)

285

Tables (1-3)

228

Sum=3918

Jun 7, 2006 (publication date) through Feb 6, 2025

Times Cited of This Article

Times Cited (50)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Clinical Research

World J Gastroenterol. Jun 7, 2006; 12(21): 3386-3392
Published online Jun 7, 2006. doi: 10.3748/wjg.v12.i21.3386

Full Size Figure Download Figure

Figure 2 Rectal NO levels in the treatment of UC and CD patients on d 1. ^bP < 0.001 vs Control; ^dP < 0.01, ^aP < 0.05 vs patients responding to treatment.

Citation: Ljung T, Lundberg S, Varsanyi M, Johansson C, Schmidt PT, Herulf M, Lundberg JO, Hellström PM. Rectal nitric oxide as biomarker in the treatment of inflammatory bowel disease: Responders versus nonresponders. World J Gastroenterol 2006; 12(21): 3386-3392
URL: https://www.wjgnet.com/1007-9327/full/v12/i21/3386.htm
DOI: https://dx.doi.org/10.3748/wjg.v12.i21.3386